Eli Lilly and Company (BKK:LLY80)

Thailand flag Thailand · Delayed Price · Currency is THB
1.340
-0.030 (-2.19%)
At close: Oct 28, 2025
-2.19%
Market Cap23.81T
Revenue (ttm)1.73T
Net Income (ttm)448.19B
Shares Outn/a
EPS (ttm)496.67
PE Ratio53.12
Forward PE29.60
Dividend0.00 (0.29%)
Ex-Dividend DateAug 15, 2025
Volume5,205
Average Volume9,859,965
Open1.350
Previous Close1.370
Day's Range1.340 - 1.350
52-Week Range1.010 - 1.430
Betan/a
RSI55.28
Earnings DateOct 30, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]

Industry Pharmaceutical Preparations
Founded 1876
Employees 47,000
Stock Exchange Stock Exchange of Thailand
Ticker Symbol LLY80
Full Company Profile

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD Financial Statements

News

There is no news available yet.